Evolution of antiretroviral treatment adherence from 2000 to 2008

Ibarra Barrueta, O.; Urrutia Losada, A.; López de Torre Querejazu, A.; Mayo Suárez, J.; Martínez Gutiérrez, E.; Martínez-Bengoechea, M.J.

doi:10.1016/S2173-5085(10)70021-6

Farmacia Hospitalaria

ISSN: 1130-6343

Farmacia Hospitalaria (Farm Hosp) is the official publication of the Spanish Society of Hospital Pharmacists (SEFH), a professional and scientific organization that currently has about 4.351 members.

The Mission of Farm Hosp is to be the support for health professionals for expanding the influence of projects, publications, and training programs, and to promote the exchange of experiences.

Vision Farm Hosp is:
- to increase the state of knowledge about the hospital pharmacy and whose actions should increase the adequate and safe use of medicines and health products.
- to be an instrument of exchange and dissemination of scientific knowledge of pharmacy practice through the best use and safe medication and health outcomes.

It is a peer-reviewed double-blind scientific journal aimed at publishing in the broad field of Hospital Pharmacy advances in Pharmacy Services. This journal included the following topics: Drug evaluation. Quality of life. Patient Reported Outcome Measures (PROMs), and Patient Reported Experience Measures (PREMs) in the use of drugs. Monitoring medication. Pharmaceutical compounding. Medication administration. Management of Pharmacy Services (logistics, quality control). Technologies and information systems in the process of using medication. Medical devices. Patient Education. Pharmacist´s role in the society and /or in the Health System in Spain, and other topics related to clinical, scientific, and institutional role of hospital pharmacists.

Farmacia Hospitalaria publishes bimonthly (6 issues yearly) originals, short originals, reviews, clinical cases, special articles, protocols, consensus documents, clinical guidelines, letters to the editor, editorials.

All the articles are published in Spanish and English language regardless of the language in which they are received.

Farmacia Hospitalaria is an Open Access journal, whose content is available free of charge to users or their institutions. Users are authorised to read, download, copy, distribute, print, search, or link to entire texts of the articles in this journal without prior permission from the editor or author, according to the BOAI definition of Open Access. The papers may be re-used under the terms of the Creative Commons 4.0 license. (CC BY-NC-ND). Such use shall be subject to authorisation from SEFH, the journal owner.

Farmacia Hospitalaria journal charges no fees for submission of papers or publication of articles.

Adherence to international ethics recommendations

Manuscripts must follow the most recent recommendations of the International Committee of Medical Journal Editors (available at http://www.icmje.org).

The articles published in Farmacia Hospitalaria are indexed in PubMed and other 17 date bases:
- Evaluation databases: MEDLINE, DOAJ, Scopus, Latindex y Scimago Journal and Country Rank (SJR). Índice H: 18, quartile 3 (Medicine, miscellaneous / Pharmacology)
- Bibliographic databases: CINHAL, EMBASE Excerpta Medica, Índice Bibliográfico Español en Ciencias de la Salud (IBECS), Índice Español de Ciencia Y Tecnología (ICyT), Índice Médico Español (IME), International Pharmaceutical Abstracts (IPA).
- Journal collections: Dialnet, Medes, Scientific Electronic Library Online (SciELO), REDIB, ScienceDirect, ClinicalKey.

Farmacia Hospitalaria ha recibido Factor de Impacto (JCR) por primera vez en 2023.
Guía para autores - Envío de manuscritos

Farmacia Hospitalaria has received its first journal Impact Factor (JCR) in 2023.
Instructions for authors - Submit an article

Indexed in:

Web of Science, Scopus, Scimago Journal and Country Rank (SJR), Índice H: 18, CINHAL, EMBASE Excerpta Medica, Índice Bibliográfico Español en Ciencias de la Salud (IBECS), Índice Español de Ciencia Y Tecnología (ICyT), Índice Médico Español (IME), International Pharmaceutical Abstracts (IPA), MEDLINE, DOAJ, Dialnet, Latindex, Medes, Scientific Electronic Library Online (SciELO), REDIB.

Descriptive study of the evolution of average annual adherence and the annual percentage of adherent patients greater than 95% from 2000 to 2008. We analysed the individual pattern of adherence over time and patients were classified as ‘consistently adherent’, ‘consistently non-adherent’, and ‘fluctuating’.

Results

In the analysis of 577 patients, baseline adherence was significantly greater in naïve patients compared to those who were pre-treated.

Average annual adherence increased slightly and stayed at values around 95%. As with the percentage of patients with adherence greater than 95%, which increased from 64% in 2000 to 79% in 2008.

In terms of the individual pattern of adherence over time, of the 468 patients analysed, the majority (59%) were consistently adherent, 4% non-adherent, and the rest (37%) fluctuated in their adherence.

Conclusions

In our cohort, the overall adherence values remained steady over time and even show a positive trend, which is likely to be the result of systematic monitoring of adherence and implementation strategies to maintain adherence.

Keywords:

Adherence

Antiretroviral therapy

Acquired immunodeficiency syndrome (AIDS)

Human immunodeficiency virus (HIV)

Resumen

Objetivos

Evaluar la adherencia al tratamiento antirretroviral en la cohorte de pacientes VIH de nuestro hospital y ver su evolución a lo largo de 9 años, así como conocer el patrón individual de la adherencia con el tiempo.

Métodos

Estudio descriptivo de la evolución de la adherencia media anual y el porcentaje anual de pacientes con adherencias superiores al 95%, desde el 2000 al 2008. Se analizó el patrón individual de adherencia con el tiempo y se clasificó a los pacientes en adherentes consistentes, no adherentes consistentes y fluctuantes.

Resultados

En el análisis de 577 pacientes, la adherencia basal fue significativamente mayor en los pacientes naive respecto a los pretratados.

La adherencia media anual aumentó ligeramente y se mantuvo en valores cercanos al 95%, al igual que el porcentaje de pacientes con adherencia superior al 95%, que aumentó desde el 64% en el 2000 al 79% en 2008.

En cuanto al patrón individual de adherencia con el tiempo, de los 468 pacientes analizados, la mayoría (59%) fueron adherentes consistentes, un 4% no adherente y el resto (37%) presentaban fluctuaciones en su adherencia.

Conclusiones

En nuestra cohorte los valores de adherencia global se mantienen con el tiempo e incluso presentan una tendencia positiva, resultado de una monitorización sistemática de la adherencia e implantación de estrategias dirigidas a mantener la adherencia.

Palabras clave:

Adherencia

Terapia antirretroviral

Síndrome de la inmunodeficiencia humana adquirida (sida)

Virus de la inmunodeficiencia humana

Full text is only aviable in PDF

References

[1.]

Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero de 2007). Panel de expertos de Gesida y Plan Nacional del Sida. Enferm Infecc Microbiol Clin. 2007;25:32-53.

[2.]

D.L. Paterson, S. Swindells, J. Mohr, M. Brester, E.N. Vergis, C. Squier, et al.

Adherence to protease inhibitor therapy and outcomes in patients with HIV infection.

Ann Intern Med, 133 (2000), pp. 21-30

Medline

[3.]

D.R. Bangsberg.

Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression.

Clin Infect Dis, 43 (2006), pp. 939-941

http://dx.doi.org/10.1086/507526 | Medline

[4.]

Recomendaciones GESIDA/SEFH/PNS para mejorar la adherencia al tratamiento antiretroviral [accessed 6/2008]. Available from: http://www.gesida.seimc.org/pcientifica/fuentes/DcyRc/Gesida_dcyrc2008_adherenciaTAR.pdf.

[5.]

S. Rueda, L.Y. Park-Wyllie, A.M. Bayoumi, A.M. Tynan, T.A. Antoniou, S.B. Rourke, et al.

Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS (Review).

Cochrane Database Syst Rev, 3 (2006), pp. CD001442

http://dx.doi.org/10.1002/14651858.CD001442.pub2 | Medline

[6.]

J.M. Simoni, C.R. Pearson, D.W. Pantalone, G. Marks, N. Crepaz.

Efficacy of intervencions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load.

J Acquir Immune Defic Syndr, 43 (2006), pp. S23-S35

http://dx.doi.org/10.1097/01.qai.0000248342.05438.52 | Medline

[7.]

N. Singh, C. Squier, C. Sivek, M. Wagener, M.H. Nguyen, V.L. Yu.

Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance.

AIDS Care, 8 (1996), pp. 261-269

[8.]

C.A. Kleeberger, J. Buechner, F. Palella, R. Detels, S. Riddler, R. Godfrey, et al.

Changes in adherence to highly active antiretroviral therapy medications in the Multicenter AIDS Cohort Study.

AIDS, 18 (2004), pp. 683-688

Medline

[9.]

D.A. Murphy, M. Belzer, S.J. Durako, M. Sarr, C.M. Wilson, L.R. Muenz.

Longitudinal antiretroviral adherence among adolescents infected with human immunodeficiency virus.

Arch Pediatr Adolesc Med, 159 (2005), pp. 764-770

http://dx.doi.org/10.1001/archpedi.159.8.764 | Medline

[10.]

Ibarra MO, Corcostegui B, Peral J, Mayo J, Mora O, Martínez-Bengoechea MJ. Efficacy of AMA intervention to improve HIV medication adherence. Oral abstract. 3rd International Conference on HIV treatment adherence. Jersey City 2008.

[11.]

E.M. Gardner, W.J. Burman, M.E. Maravi, A.J. Davidson.

Selective drug taking during combination antiretroviral therapy in an unselected clinic population.

J Acquir Immune Defic Syndr, 40 (2005), pp. 294-300

Medline

[12.]

A.E. Deschamps, S. De Geest, A.M. Vandame, H. Bobbaers, W.E. Peetermans, E. Van Wijngaerden.

Diagnostic value of different adherence measures using electronic monitoring and virologic failure as reference standards.

AIDS Patient Care, 22 (2008), pp. 1-9

[13.]

J.A. Muñoz- Moreno, C.R. Fumaz, M.J. Ferrer, A. Tuldrà, T. Rovira, C. Viladrich, et al.

Assessing self-reported adherence to HIV therapy by questionnaire: The SERAD (Self-reported adherence) Study.

AIDS Res Hum retroviruses, 23 (2007), pp. 1166-1175

http://dx.doi.org/10.1089/aid.2006.0120 | Medline

[14.]

M. Lazo, S.J. Gange, T.E. Wilson, K. Anastos, D.G. Ostrow, M.D. Witt, et al.

Patterns and predictors of changes in adherence to highly active antiretroviral therapy: longitudinal study of men and women.

Clin Infect Dis, 45 (2007), pp. 1377-1385

http://dx.doi.org/10.1086/522762 | Medline

[15.]

V.D. Lima, R. Harrigan, D.R. Bangsberg, R.S. Hogg, R. Gross, B. Yip, et al.

The combined effect of moderm highly active antiretroviral therapy regimens and adherence on mortality over time.

J Acquir Immune Defic Syndr, 50 (2009), pp. 529-536

http://dx.doi.org/10.1097/QAI.0b013e31819675e9 | Medline

[16.]

V. Cooper, G. Gellaitry, M. Hankins, M. Fisher, R. Horne.

The influence of symptom experiences and attributions on adherence to highly active antiretroviral therapy (HAART): a six- month prospective, follow-up study.

AIDS Care, 21 (2009), pp. 520-528

[17.]

L.N. Schonnesson, P.M. Diamond, M.W. Ross, M. Williams, G. Bratt.

Baseline predictors of three types of antiretroviral therapy (ART) adherence: a 2- year follow-up.

AIDS Care, 4 (2006), pp. 406-414

[18.]

Ibarra Barrueta MO, Martínez Gutiérrez E, Mayo Suárez J, Gabilondo Zelaia I. Adherence can be maintained over time after intensive intervention. 4th International Conference on HIV treatment adherence Miami. 2009.

[19.]

N.J. Ostrop, K.A. Hallett, J. Gill.

Long- term patient adherence to antiretroviral therapy.

Ann Pharmacother, 34 (2000), pp. 703-709

Medline

[20.]

O. Ibarra Barrueta, L. Ortega Valín, on behalf of Grupo VIH de la SEFH.

Encuesta de la situación de la Atención Farmacéutica en el paciente VIH en España.

Farm Hosp, 32 (2008), pp. 196-203

[21.]

R. Gross, B. Yip, V. Lo Re, E. Wood, C.S. Alexander, P.R. Harrigan, et al.

A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression.

J Infect Dis, 194 (2006), pp. 1108-1114

http://dx.doi.org/10.1086/507680 | Medline

[22.]

R. Grossberg, Y. Zhang, R. Gross.

A time-to- prescription- refill measure of antiretroviral adherence predicted changes in viral load in HIV.

J Clin Epidemiol, 57 (2004), pp. 7-1110

[23.]

E.M. Gardner, W.J. Burman, M.E. Maravi, A.J. Davidson.

Durability of adherence to antiretroviral therapy on initial and subsequent regimens.

AIDS Patient Care STDS, 20 (2006), pp. 628-636

[24.]

W.C. Holmes, W.B. Bilker, H. Wang, J. Chapman, R. Gross.

HIV/AIDSspecific quality of life and adherence to antiretroviral therapy over time.

J Acquir Inmune Defic Syndr, 46 (2007), pp. 323-327

☆

This study was presented as an Oral Communication, number CT4, in the 5th Sei Norte Conference, held in San Sebastian from 7–9 May 2009.

Tools

Publish in

Farmacia Hospitalaria

Farmacia Hospitalaria follows the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals

Indexed in:

Follow us:

Subscribe to our newsletter